Emerald Advisers’s Deciphera Pharmaceuticals, Inc. Common Stock DCPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-1,044,871
| Closed | -$16.4M | – | 276 |
|
|
2024
Q1 | $16.4M | Buy |
1,044,871
+373,616
| +56% | +$5.75M | 0.66% | 62 |
|
|
2023
Q4 | $10.8M | Buy |
+671,255
| New | +$8.56M | 0.46% | 89 |
|
|
2021
Q3 | – | Sell |
-8,865
| Closed | -$325K | – | 295 |
|
|
2021
Q2 | $325K | Sell |
8,865
-276,981
| -97% | -$10.7M | 0.01% | 217 |
|
|
2021
Q1 | $12.8M | Sell |
285,846
-39,280
| -12% | -$1.83M | 0.46% | 91 |
|
|
2020
Q4 | $18.6M | Buy |
325,126
+60,495
| +23% | +$3.59M | 0.62% | 72 |
|
|
2020
Q3 | $13.6M | Buy |
264,631
+62,917
| +31% | +$3.08M | 0.56% | 72 |
|
|
2020
Q2 | $12M | Buy |
201,714
+98,204
| +95% | +$5.25M | 0.52% | 72 |
|
|
2020
Q1 | $4.26M | Buy |
+103,510
| New | +$5.75M | 0.25% | 104 |
|
|
2019
Q4 | – | Sell |
-8,010
| Closed | -$272K | – | 352 |
|
|
2019
Q3 | $272K | Sell |
8,010
-390,411
| -98% | -$11.6M | 0.01% | 216 |
|
|
2019
Q2 | $8.98M | Sell |
398,421
-4,613
| -1% | -$108K | 0.36% | 98 |
|
|
2019
Q1 | $9.35M | Sell |
403,034
-219,870
| -35% | -$5.75M | 0.38% | 98 |
|
|
2018
Q4 | $13.1M | Sell |
622,904
-81,610
| -12% | -$2.01M | 0.64% | 63 |
|
|
2018
Q3 | $27.3M | Buy |
704,514
+112,290
| +19% | +$4.15M | 1% | 25 |
|
|
2018
Q2 | $23.3M | Buy |
592,224
+110,785
| +23% | +$3.26M | 0.88% | 40 |
|
|
2018
Q1 | $9.65M | Sell |
481,439
-1,187
| -0.2% | -$30.1K | 0.39% | 105 |
|
|
2017
Q4 | $10.9M | Buy |
482,626
+131,886
| +38% | +$2.58M | 0.42% | 96 |
|
|
2017
Q3 | $6.66M | Buy |
+350,740
| New | +$6.43M | 0.27% | 111 |
|
Other funds holding DCPH
Emerald Advisers's DCPH Position: Q2 2024 in Review
Emerald Advisers sold out of Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) in Q2 2024, closing a stake of 1,044,871 shares — an estimated $16.4M sold.
Emerald Advisers first reported a position in DCPH in Q3 2017 and held it in 17 quarters. The position peaked at $27.3M in Q3 2018. 1 fund tracked by Wall St. Rank holds DCPH as of Q2 2024.
- Emerald Advisers reported no remaining Deciphera Pharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- Emerald Advisers sold 1,044,871 Deciphera Pharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $16.4M.
- Emerald Advisers first reported a position in Deciphera Pharmaceuticals, Inc. Common Stock in Q3 2017 and held it in 17 quarters.
- Emerald Advisers's Deciphera Pharmaceuticals, Inc. Common Stock position peaked at $27.3M in Q3 2018.
- 1 fund tracked by Wall St. Rank held Deciphera Pharmaceuticals, Inc. Common Stock as of Q2 2024.
Based on Emerald Advisers's 13F filing for Q2 2024, filed 6 Aug 2024.